Table 1.
Demographics and disease characteristics at study entry
| AAPa | AAP-PD | |||
|---|---|---|---|---|
| All patient (N = 754) |
Patients with CV comorbidities (n = 504) |
All patients (N = 394) |
Patients with CV comorbidities (n = 234) |
|
| Age, y, median (range) | 76.0 (43–98) | 77.0 (50–94) | 70.0 (46–89) | 72.0 (48–89) |
| Time from initial prostate cancer diagnosis to study inclusion, y, median (range) | 5.0 (0–29) | 5.3 (0–29) | 3.7 (0–20) | 4.3 (0–18) |
| Site of lesion, n (%) | (n = 612) | (n = 402) | (n = 345) | (n = 202) |
| Node | 249 (40.7) | 167 (41.5) | 155 (44.9) | 96 (47.5) |
| Liver and lung | 7 (1.1) | 5 (1.2) | 7 (2.0) | 4 (2.0) |
| Liver only | 13 (2.1) | 7 (1.7) | 25 (7.2) | 17 (8.4) |
| Lung only | 39 (6.4) | 25 (6.2) | 29 (8.4) | 19 (9.4) |
| Local recurrence | 85 (13.9) | 54 (13.4) | 70 (20.3) | 42 (20.8) |
| Bone | 463 (75.7) | 296 (73.6) | 261 (75.7) | 155 (76.7) |
| Other | 52 (8.5) | 31 (7.7) | 37 (10.7) | 21 (10.4) |
| Presence of bone metastases (baseline), n (%) | (n = 550) | (n = 374) | (n = 271) | (n = 169) |
| Any | 487 (88.5) | 328 (87.7) | 238 (87.8) | 145 (85.8) |
| ≥ 5 | 203 (36.9) | 134 (35.8) | 113 (41.7) | 75 (44.4) |
| Visceral metastases (baseline), n (%) | (n = 612) | (n = 402) | (n = 345) | (n = 202) |
| Liver only | 13 (2.1) | 7 (1.7) | 25 (7.2) | 17 (8.4) |
| Lung only | 39 (6.4) | 25 (6.2) | 29 (8.4) | 19 (9.4) |
| Liver and lung | 7 (1.1) | 5 (1.2) | 7 (2.0) | 4 (2.0) |
| Biological parameters, median (range) | ||||
| Prostate-specific antigen, ng/mL | 34.40 (0.0–10,710.0) | 34.00 (0.1–10,710.00) | 50.45 (0.0 –2108.0) | 52.4 (0.1 –1445.0) |
| Lactic acid dehydrogenase, U/L | 268.0 (3–3870) | 255.0 (3–3870) | 307.0 (40.0 –3537.0) | 291.0 (103.0 –1553.0) |
| Alkaline phosphatase, U/L | 111.0 (1–2890) | 112.5 (1–2890) | 103.2 (1.0 –1850.0) | 104.0 (1.0 –1433.0) |
| Hemoglobin, g/dL | 12.9 (7–17) | 12.7 (7–16) | 12.5 (7.0 –17.0) | 12.4 (7.0 –16.0) |
| Gleason score at initial diagnosis, n (%) | (n = 674) | (n = 448) | (n = 367) | (n = 220) |
| 2–6 | 100 (14.8) | 71 (15.8) | 44 (12.0) | 31 (14.1) |
| 7 | 230 (34.1) | 154 (34.4) | 106 (28.9) | 63 (28.6) |
| 8–10 | 344 (51.0) | 223 (49.8) | 217 (59.1) | 126 (57.3) |
| M stage at initial diagnosis, n (%) | (n = 732) | (n = 488) | (n = 388) | (n = 230) |
| Mx | 161 (22.0) | 114 (23.4) | 73 (18.8) | 44 (19.1) |
| M0 | 315 (43.0) | 217 (44.5) | 138 (35.6) | 89 (38.7) |
| M1, M1a, M1b, M1c | 256 (35.0) | 157 (32.2) | 177 (45.6) | 97 (42.2) |
| ECOG performance status, n (%) | (n = 715) | (n = 477) | (n = 371) | (n = 221) |
| 0 | 340 (47.6) | 218 (45.7) | 133 (35.8) | 72 (32.6) |
| 1 | 318 (44.5) | 214 (44.9) | 208 (56.1) | 127 (57.5) |
| 2 | 48 (6.7) | 6 (7.5) | 26 (7.0) | 19 (8.6) |
| 3 | 9 (1.3) | 9 (1.9) | 4 (1.1) | 3 (1.4) |
| 4 | 0 | 0 | 0 | 0 |
AAP abiraterone acetate plus prednisone/prednisolone, AAP-PD AAP after docetaxel, CV cardiovascular, ECOG Eastern Cooperative Oncology Group
aIncluded for comparative purposes